Therapeutic potential of the dual peroxisome proliferator activated receptor (PPAR)?/? agonist aleglitazar in attenuating TNF-?-mediated inflammation and insulin resistance in human adipocytes.

Torna indietro

Abstract

Adipose tissue inflammation is a mechanistic link between obesity and its related sequelae, including insulin resistance and type 2 diabetes. Dual ligands of peroxisome proliferator activated receptor (PPAR)? and ?, combining in a single molecule the metabolic and inflammatory-regulatory properties of ? and ? agonists, have been proposed as a promising therapeutic strategy to antagonize adipose tissue inflammation. Here we investigated the effects of the dual PPAR?/? agonist aleglitazar on human adipocytes challenged with inflammatory stimuli. Human Simpson-Golabi-Behmel syndrome (SGBS) adipocytes were treated with aleglitazar or - for comparison - the selective agonists for PPAR? or ? fenofibrate or rosiglitazone, respectively, for 24 h before stimulation with TNF-?. Aleglitazar, at concentrations as low as 10 nmol/L, providing the half-maximal transcriptional activation of both PPAR? and PPAR?, reduced the stimulated expression of several pro-inflammatory mediators including interleukin (IL)-6, the chemokine CXC-L10, and monocyte chemoattractant protein (MCP)-1. Correspondingly, media from adipocytes treated with aleglitazar reduced monocyte migration, consistent with suppression of MCP-1 secretion. Under the same conditions, aleglitazar also reversed the TNF-?-mediated suppression of insulin-stimulated ser473 Akt phosphorylation and decreased the TNF-?-induced ser312 IRS1 phosphorylation, two major switches in insulin-mediated metabolic activities, restoring glucose uptake in insulin-resistant adipocytes. Such effects were similar to those obtainable with a combination of single PPAR? and ? agonists. In conclusion, aleglitazar reduces inflammatory activation and dysfunction in insulin signaling in activated adipocytes, properties that may benefit diabetic and obese patients. The effect of aleglitazar was consistent with dual PPAR? and ? agonism, but with no evidence of synergism.

Autore Pugliese

Tutti gli autori

  • Massaro M.; Scoditti E.; Pellegrino M.; Carluccio M.A.; Calabriso N.; Wabitsch M.; Storelli C.; Wright M.; De Caterina R.

Titolo volume/Rivista

Pharmacological research

Anno di pubblicazione

2016

ISSN

1043-6618

ISBN

Non Disponibile

Numero di citazioni Wos

Nessuna citazione

Ultimo Aggiornamento Citazioni

Non Disponibile

Numero di citazioni Scopus

Non Disponibile

Ultimo Aggiornamento Citazioni

Non Disponibile

Settori ERC

Non Disponibile

Codici ASJC

Non Disponibile